Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29258030 | 0.97 | LMNA (0.46) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL7563578 | 0.97 | LMNA (0.46) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL25219703 | 0.97 | LMNA (0.46) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL2491467 | 0.91 | — | — | |
| SCHEMBL7863608 | 0.81 | PTPN1 (0.36) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL7863942 | 0.79 | PTPN1 (0.35) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL11187190 | 0.78 | — | — | |
| SCHEMBL290187 | 0.78 | PAOX (0.48) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL22788376 | 0.78 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL28899562 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | claimed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | claimed |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS (US) | 2013-08-15 | — | — | US | claimed |
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | disclosed |
| EP-3262056-A2 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | Sarepta Therapeutics, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9809521-B2 | Cannabidinoid derivatives | SUTTER WEST BAY HOSPITALS (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2017184529-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20160376211-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2016-12-29 | — | — | US | disclosed |
| WO-2016138534-A2 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-9254272-B2 | Resorcinol derivatives | SUTTER WEST BAY HOSPITALS (US) | 2016-02-09 | — | — | US | disclosed |
| EP-1053241-A1 | NOVEL DIMERIZING AGENTS, THEIR PRODUCTION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-11-22 | — | — | EP | disclosed |
| EP-1030853-A1 | NOVEL SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM | ARIAD PHARMACEUTICALS, INC. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000027802-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM & USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-1999041258-A1 | NOVEL DIMERIZING AGENTS, THEIR PRODUCTION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999024442-A1 | NOVEL SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM | ARIAD PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0276124-B1 | PROSTAGLANDIN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sankyo Company Limited (JP) | 1992-05-20 | — | — | EP | disclosed |
| US-4981872-A | ANTIULCER | SANKYO COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
| US-4935426-A | FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1990-06-19 | — | — | US | disclosed |
| EP-0276124-A2 | Prostaglandin derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202322-B2 | Resorcinol derivatives | CNR1, CNR2, RCOR1 | LMNA 3370/4885KDM4C 480/4885KDM4A 1139/4885 |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | CNR2, CNR1, GPR18 | LMNA 2282/4885KDM4C 1135/4885KDM4A 1526/4885 |
| US-20160376211-A1 | CANNABIDINOID DERIVATIVES | CNR2, CNR1, GPR18 | LMNA 2282/4885KDM4C 1135/4885KDM4A 1526/4885 |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | CNR1, CNR2, RCOR1 | LMNA 3370/4885KDM4C 480/4885KDM4A 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.